Prognostic Differences of RAS Mutations: Results from the South Australian Metastatic Colorectal Registry

Anas Alawawdeh, Cynthia Piantadosi, Amanda Rose Townsend, Christos Stelios Karapetis, Rob Padbury, Amitesh Chandra Roy, James Moore, Guy Maddern, David Roder, Annabelle Smith, Timothy Jay Price

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Effective targeting of RAS mutations has proven elusive until recently. Novel agents directly targeting KRAS G12C have shown promise in early-phase clinical trials that included patients with metastatic colorectal cancer. Prior reports have suggested that G12C mutation may be predictive of poor outcome. 

Objective: Assessment of the specific characteristics and prognostic implications of individual RAS mutation subtypes in patients with metastatic colorectal cancer. 

Patients and methods: Retrospective review of individual RAS mutation types from the South Australian Metastatic Colorectal Registry between 2006 and 2020. 

Results: Of the 5165 patients entered onto the registry, 2305 (45%) had RAS mutation results available. 772 (33%) had a RAS mutation. The nature of the RAS mutation was available in 668 (87% of those with RAS mutation). Rare mutations (outside codons 12 and 13) made up 12.6% of the total. There were numerical differences in survival between the specific RAS mutation subgroups, with the longest median overall survival (30 months) observed in those with G12S mutations. However, there was no statistical difference in survival when comparing the various RAS mutations, including the comparison of G12C to G12S (p = 0.38). Patients with cancer harbouring rare RAS mutations had a median survival of 30 months. 

Conclusions: Whilst the G12S mutation was associated with the longest survival numerically, the observed survival for patients with the most common RAS mutations (G12C, G12V, G12A, G12D and G13D) did not significantly differ.

Original languageEnglish
Pages (from-to)35-41
Number of pages7
JournalTargeted Oncology
Volume17
Issue number1
Early online date25 Nov 2021
DOIs
Publication statusPublished - Jan 2022

Keywords

  • Metastatic colorectal cancer
  • RAS mutations
  • Patient outcomes

Fingerprint

Dive into the research topics of 'Prognostic Differences of RAS Mutations: Results from the South Australian Metastatic Colorectal Registry'. Together they form a unique fingerprint.

Cite this